R13
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 93
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.770
- INTERFERON_GAMMA_RESPONSE+0.690
- ALLOGRAFT_REJECTION+0.630
- INFLAMMATORY_RESPONSE+0.510
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.490
- IL6_JAK_STAT3_SIGNALING+0.430
- COMPLEMENT+0.420
- TNFA_SIGNALING_VIA_NFKB+0.330
- IL2_STAT5_SIGNALING+0.320
- KRAS_SIGNALING_UP+0.310
Top 10 suppressed
- E2F_TARGETS-0.460
- G2M_CHECKPOINT-0.380
- MYC_TARGETS_V2-0.350
- MITOTIC_SPINDLE-0.340
- TGF_BETA_SIGNALING-0.340
- UV_RESPONSE_DN-0.280
- WNT_BETA_CATENIN_SIGNALING-0.270
- MYC_TARGETS_V1-0.250
- CHOLESTEROL_HOMEOSTASIS-0.230
- UNFOLDED_PROTEIN_RESPONSE-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A0B6-01A-11R-A19W-07 | — | D | 0.895 |
| 2 | SAMN03290925 | — | — | 0.871 |
| 3 | TCGA-E2-A1B5-01A-21R-A12P-07 | — | D | 0.871 |
| 4 | f5760366-59eb-417d-a935-3f78e999dd42 | — | — | 0.865 |
| 5 | 0ec02d90-7ccb-476e-a8bb-9a9c8f158dee | — | — | 0.864 |
| 6 | ad2bbb19-6d02-480f-b011-d4327c3c5607 | — | — | 0.832 |
| 7 | da7cbc0a-95dc-4303-a5dd-75857c066f3b | — | — | 0.824 |
| 8 | TCGA-5L-AAT1-01A-12R-A41B-07 | — | A | 0.822 |
| 9 | SRR35579799 | — | D | 0.822 |
| 10 | TCGA-75-5122-01A-01R-1755-07 | — | cohortA1 | 0.819 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.770 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.690 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.630 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.510 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.490 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.430 | Inavolisib | — uncovered |
| COMPLEMENT | 0.420 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.330 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.320 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.310 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.260 | Remibrutinib | — uncovered |
| COAGULATION | 0.230 | Binimetinib | — uncovered |
| APOPTOSIS | 0.190 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.180 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.160 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.140 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.140 | Cobimetinib | — uncovered |
| HEME_METABOLISM | 0.130 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.130 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.050 | Inavolisib | — uncovered |